KabozantiniCabozantinib in the treatment of patients with renal cell carcinomab v léčbě pacientů s renálním karcinomem
01/2019
MUDr. Jana Katolická, Ph.D.1; MUDr. Jiří Vaníček, Ph.D.2
1 Onkologicko-chirurgické oddělení, FN u svaté Anny, Brno
2 Klinika zobrazovacích metod, FN u svaté Anny, Brno
SUMMARY
Cabozantinib is a novel multitargeted tyrosine kinase inhibitor that improved progression-free survival and overall survival in patients with advanced renal cell carcinoma after one or more prior vascular endothelial growth factor receptor targeted therapies. The safety profile of cabozantinib is acceptable.
KEY WORDS
metastatic renal cancer, cabozantinib
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...